Regeneron Pharmaceuticals... (REGN)
NASDAQ: REGN
· Real-Time Price · USD
583.24
-2.24 (-0.38%)
At close: Oct 07, 2025, 3:59 PM
586.00
0.47%
After-hours: Oct 07, 2025, 07:57 PM EDT
-0.38% (1D)
| Bid | 578.53 |
| Market Cap | 60.76B |
| Revenue (ttm) | 14.21B |
| Net Income (ttm) | 4.46B |
| EPS (ttm) | 39.66 |
| PE Ratio (ttm) | 14.71 |
| Forward PE | 14.93 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 595 |
| Volume | 628,662 |
| Avg. Volume (20D) | 1,236,514.9 |
| Open | 587.59 |
| Previous Close | 585.48 |
| Day's Range | 578.42 - 591.45 |
| 52-Week Range | 476.49 - 1024.36 |
| Beta | 0.31 |
| Ex-Dividend Date | n/a |
About REGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol REGN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for REGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsRegeneron Pharmaceuticals Inc. is scheduled to release its earnings on
Oct 28, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 days ago
Shares of many drugmakers are trading higher after...
Unlock content with
Pro Subscription
4 weeks ago
Regeneron Pharmaceuticals shares are trading lower. The company announced results evaluating its first-in-class investigational allergen-blocking antibodies in allergen-challenge Phase 3 trials in adults with moderate-to-severe cat or birch allergies.
4 days ago · proactiveinvestors.com
Regeneron Pharmaceuticals catalysts could drive stock higher: analystsJP Morgan analysts see an “attractive setup” for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares, believing the company's Dupixent and Eylea drugs and cash on hand alone support valuation at curren...
